T1	Participants 54 84	progressive Multiple Sclerosis
T2	Participants 282 332	patients with progressive multiple sclerosis (MS).
T3	Participants 884 1085	single centre (Bristol, UK). Eighty patients with progressive MS will be recruited; 60 will have secondary progressive disease (SPMS) but a subset (n = 20) will have primary progressive disease (PPMS).